文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

不同的肿瘤浸润淋巴细胞图谱与局限性非小细胞肺癌的临床结局相关。

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.

机构信息

Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, USA.

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.

出版信息

Ann Oncol. 2022 Jan;33(1):42-56. doi: 10.1016/j.annonc.2021.09.021. Epub 2021 Oct 13.


DOI:10.1016/j.annonc.2021.09.021
PMID:34653632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10019222/
Abstract

BACKGROUND: Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established. PATIENTS AND METHODS: Fresh tumor and normal adjacent tissue was prospectively collected from 150 patients with localized NSCLC. Tissue was comprehensively characterized by high-dimensional flow cytometry of TILs integrated with immunogenomic data from multiplex immunofluorescence, T-cell receptor sequencing, exome sequencing, RNA sequencing, targeted proteomics, and clinicopathologic features. RESULTS: While neither the magnitude of TIL infiltration nor specific TIL subsets were significantly prognostic alone, the integration of high-dimensional flow cytometry data identified two major immunotypes (IM1 and IM2) that were predictive of recurrence-free survival independent of clinical characteristics. IM2 was associated with poor prognosis and characterized by the presence of proliferating TILs expressing cluster of differentiation 103, programmed cell death protein 1, T-cell immunoglobulin and mucin-domain containing protein 3, and inducible T-cell costimulator. Conversely, IM1 was associated with good prognosis and differentiated by an abundance of CD8 T cells expressing cytolytic enzymes, CD4 T cells lacking the expression of inhibitory receptors, and increased levels of B-cell infiltrates and tertiary lymphoid structures. While increased B-cell infiltration was associated with good prognosis, the best prognosis was observed in patients with tumors exhibiting high levels of both B cells and T cells. These findings were validated in patient tumors from The Cancer Genome Atlas. CONCLUSIONS: Our study suggests that although the number of infiltrating T cells is not associated with patient survival, the nature of the infiltrating T cells, resolved in distinct TIL immunotypes, is prognostically relevant in NSCLC and may inform therapeutic approaches to clinical care.

摘要

背景:尽管肿瘤浸润性 T 淋巴细胞(TIL)在癌症生物学中具有重要意义,但 TIL 表型与局部非小细胞肺癌(NSCLC)的预后相关性尚未得到充分确立。

患者和方法:前瞻性收集了 150 例局部 NSCLC 患者的新鲜肿瘤和正常相邻组织。通过高维流式细胞术对 TIL 进行全面表征,整合了来自多重免疫荧光、T 细胞受体测序、外显子组测序、RNA 测序、靶向蛋白质组学和临床病理特征的免疫基因组学数据。

结果:虽然 TIL 浸润的程度或特定 TIL 亚群本身并没有显著的预后意义,但高维流式细胞术数据的整合确定了两种主要的免疫型(IM1 和 IM2),它们独立于临床特征预测无复发生存。IM2 与预后不良相关,其特征是表达分化簇 103、程序性细胞死亡蛋白 1、T 细胞免疫球蛋白和粘蛋白结构域包含蛋白 3 和诱导性 T 细胞共刺激物的增殖性 TIL。相反,IM1 与良好的预后相关,其特征是表达细胞毒性酶的 CD8 T 细胞丰富、缺乏抑制性受体表达的 CD4 T 细胞和增加的 B 细胞浸润和三级淋巴结构。虽然增加的 B 细胞浸润与良好的预后相关,但在肿瘤中同时具有高水平 B 细胞和 T 细胞的患者预后最佳。这些发现在癌症基因组图谱中的患者肿瘤中得到了验证。

结论:我们的研究表明,尽管浸润 T 细胞的数量与患者的生存无关,但浸润 T 细胞的性质,在不同的 TIL 免疫型中得到解决,与 NSCLC 的预后相关,并可能为临床治疗提供治疗方法。

相似文献

[1]
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.

Ann Oncol. 2022-1

[2]
Antigen-Presenting Intratumoral B Cells Affect CD4 TIL Phenotypes in Non-Small Cell Lung Cancer Patients.

Cancer Immunol Res. 2017-8-28

[3]
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.

J Immunother Cancer. 2021-12

[4]
Functional Heterogeneity of CD4 Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC.

Front Immunol. 2018-11-16

[5]
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

J Thorac Oncol. 2017-12-18

[6]
Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.

Anticancer Res. 2021-8

[7]
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.

J Egypt Natl Canc Inst. 2018-12

[8]
APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.

BMC Cancer. 2021-3-6

[9]
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.

Med Oncol. 2018-1-31

[10]
Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.

Clin Lung Cancer. 2018-9-24

引用本文的文献

[1]
Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.

Front Pharmacol. 2025-7-25

[2]
Emerging Techniques of Translational Research in Immuno-Oncology: A Focus on Non-Small Cell Lung Cancer.

Cancers (Basel). 2025-7-4

[3]
Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer.

J Immunother Cancer. 2025-6-24

[4]
Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.

Cancer Metastasis Rev. 2025-6-17

[5]
CEBPB regulates ERK1/2 activity through SOS1 and contributes to ovarian cancer progression.

Med Oncol. 2025-6-7

[6]
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.

J Thorac Oncol. 2025-6-3

[7]
Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy.

Discov Oncol. 2025-6-2

[8]
Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer.

Vaccines (Basel). 2025-5-14

[9]
The role of B cell immunity in lung adenocarcinoma.

Genes Immun. 2025-5-13

[10]
Dual functional nanoplatforms potentiate osteosarcoma immunotherapy via microenvironment modulation.

Natl Sci Rev. 2025-1-10

本文引用的文献

[1]
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.

Nat Immunol. 2020-11

[2]
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.

Nat Cancer. 2020-5

[3]
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort.

J Immunother Cancer. 2020-4

[4]
Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Nat Commun. 2020-1-30

[5]
B cells are associated with survival and immunotherapy response in sarcoma.

Nature. 2020-1-15

[6]
B cells and tertiary lymphoid structures promote immunotherapy response.

Nature. 2020-1-15

[7]
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

Nature. 2020-1-15

[8]
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

J Clin Invest. 2019-11-1

[9]
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

N Engl J Med. 2019-9-28

[10]
The promise of Immuno-oncology: implications for defining the value of cancer treatment.

J Immunother Cancer. 2019-5-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索